Advanced glycation end products and vascular structure and function
Diabetes mellitus has now reached epidemic proportions in the Western world. The associated microvascular and macrovascular complications are a result of severe metabolic derangement, which leads to chronic tissue injury. Although there are a number of proposed pathophysiologic mechanisms for the vascular complications associated with diabetes, this review focuses predominantly on the role of advanced glycation end products (AGEs) in the pathogenesis of diabetes-associated atherosclerosis. The potential role of AGEs in enhancing arterial stiffness, an entity occurring with a greater prevalence in populations known to have higher-than-normal AGE levels, is also examined. Pharmacologic interventions aimed at reducing the level of these chemical compounds or interrupting their action provide hope for the future treatment of both atherosclerotic vascular disease and systolic hypertension, particularly in the setting of diabetes.
KeywordsArterial Stiffness Irbesartan Macrovascular Complication Arterioscler Thromb Vasc Biol Arterial Compliance
Unable to display preview. Download preview PDF.
References and Recommended Reading
- 1.King GL, Wakasaki H: Theoretical mechanisms by which hyperglycemia and insulin resistance could cause cardiovascular diseases in diabetes. Diabetes Care 1999, 22 Suppl 3:C31-C37.Google Scholar
- 2.The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993, 329:977–986.Google Scholar
- 25.Schram MT, Henry RM, van Dijk RA, et al.: Increased central artery stiffness in impaired glucose metabolism and type 2 diabetes: the Hoorn Study. Hypertension 2004, 43:176–181. This population-based study of 619 patients demonstrates how central and peripheral arterial stiffness is independently associated with impaired glucose tolerance and frank diabetes.PubMedCrossRefGoogle Scholar
- 50.Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998, 352:837–853.Google Scholar